Fresenius SE & Co KGaA (FRE) Given a €45.00 Price Target at Morgan Stanley

Morgan Stanley set a €45.00 ($52.33) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other equities analysts have also recently weighed in on the company. Deutsche Bank set a €65.00 ($75.58) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Tuesday, April 9th. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, April 2nd. Goldman Sachs Group set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Friday, March 22nd. Kepler Capital Markets set a €62.00 ($72.09) price target on Fresenius SE & Co KGaA and gave the company a buy rating in a report on Monday, March 11th. Finally, Jefferies Financial Group set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA and gave the company a neutral rating in a report on Thursday, March 7th. Ten investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Fresenius SE & Co KGaA has a consensus rating of Buy and a consensus target price of €59.02 ($68.63).

FRA FRE opened at €50.27 ($58.45) on Tuesday. Fresenius SE & Co KGaA has a 1-year low of €60.16 ($69.95) and a 1-year high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: What are Closed-End Mutual Funds?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit